Related references
Note: Only part of the references are listed.Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic
Ko Un Park et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Larissa A. Korde et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study
Rajiv V. Dave et al.
BRITISH JOURNAL OF CANCER (2021)
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx
Lynne Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Breast Cancer, Version 3.2020
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?
Giacomo Montagna et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma
M. J. Thornton et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach
Anna Weiss et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study
Nobuaki Sato et al.
CANCER MEDICINE (2018)
Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling
Lisa Goto-Yamaguchi et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study
Akiko Chiba et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Pre-operative Endocrine Therapy
Laura M. Arthur et al.
CURRENT BREAST CANCER REPORTS (2017)
Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice
H. Cain et al.
CLINICAL ONCOLOGY (2017)
Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised?
Yara Feliciano et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients
Hiba El Hage Chehade et al.
AMERICAN JOURNAL OF SURGERY (2016)
Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance)
Bruce G. Haffty et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection
Abigail S. Caudle et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer A Systematic Review and Meta-analysis
Laura M. Spring et al.
JAMA ONCOLOGY (2016)
Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study
Jean-Francois Boileau et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial
Judy C. Boughey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
Thorsten Kuehn et al.
LANCET ONCOLOGY (2013)
Targeting Adjuvant Chemotherapy: A Good Idea That Needs to Be Proven!
Daniel F. Hayes
JOURNAL OF CLINICAL ONCOLOGY (2012)
Is Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer?
Alan S. Coates et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Defining the Benefits of Neoadjuvant Chemotherapy for Breast Cancer
Anne F. Schott et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
Stephen B. Edge et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Molecular response to aromatase inhibitor treatment in primary breast cancer
Alan Mackay et al.
BREAST CANCER RESEARCH (2007)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
W Eiermann et al.
ANNALS OF ONCOLOGY (2001)
Share Paper
